Evidence map›Paper›PMID 39456063›Full record

ArticleAsia-Pacific journal of clinical oncology2025

Expert consensus on the optimal management of BRAF

Oliver Piercey, Lorraine Chantrill, Hung-Chih Hsu, Brigette Ma, Timothy Price, Iain Beehuat Tan, Hao-Wei Teng, Jeanne Tie, Jayesh Desai

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Asia-Pacific journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Real-world characteristics and outcomes of patients with BRAFESMO real world data and digital oncology · 2025
    Article
  3. Expert consensus on the optimal management of BRAFAsia-Pacific journal of clinical oncology · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Oliver PierceyPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0003-2220-2570
Lorraine ChantrillIllawarra Shoalhaven Local Health District, Illawarra, New South Wales, Australia.ORCID https://orcid.org/0000-0002-5790-0208
Hung-Chih HsuDivision of Hematology Oncology, Chang Gung Memorial Hospital, New Taipei, Taiwan.
Brigette MaState Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR, China.
Timothy PriceThe Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Iain Beehuat TanDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID https://orcid.org/0000-0003-4951-0354
Hao-Wei TengDepartment of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID https://orcid.org/0000-0001-8480-3422
Jeanne TiePeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0001-9244-2057
Jayesh DesaiPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0003-4246-9344

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The burden of colorectal cancer (CRC) is high in the Asia-Pacific region, and several countries in this region have among the highest and/or fastest growing rates of CRC in the world. A significant proportion of patients will present with or develop metastatic CRC (mCRC), and BRAF

Indexed as

Colorectal NeoplasmsProto-Oncogene Proteins B-rafAsiaConsensusHumansMutationNeoplasm MetastasisBRAF protein, humanProto-Oncogene Proteins B-rafAsia‐PacificBRAFV600E mutationimmunotherapymetastatic colorectal cancertargeted therapy

Identifiers

PMID39456063
PMCPMC11733838

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.